Fertility and sterility · 2026
Euploidy rates are comparable between progestin protocol ovarian stimulation and gonadotropin-releasing hormone antagonist protocol ovarian stimulation cycles.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ata Baris, Lawrenz Barbara, Kalafat Erkan, Del Gallego Raquel, Melado Laura, Elkhatib Ibrahim, Fatemi Human M
Аннотация
OBJECTIVE: To compare blastocyst euploidy rates between progestin protocol ovarian stimulation and gonadotropin-releasing hormone (GnRH) antagonist protocol ovarian stimulation cycles.
DESIGN: Retrospective cohort study.
SUBJECTS: Women undergoing assisted reproductive technology cycles with their own oocytes.
EXPOSURE: Ovarian stimulation was commenced on day 2/3 of the cycle, and either the GnRH-antagonist protocol was employed or the progestin protocol with dydrogesterone at a dose of 30 mg/d in three divided doses was started on the same day with gonadotropins or the day after and continued until (including) the day of final oocyte maturation.
MAIN OUTCOME MEASURES: Blastocyst euploidy rates.
RESULTS: A total of 4,755 stimulation cycles were included in the study, and 973 GnRH antagonist and 398 propensity score-matched progestin protocol cycles were included in the analyses. In bivariate comparisons, mature oocyte yield, number of zygotes, blastocysts, euploid blastocysts, and euploidy rate per biopsied blastocyst were similar between the groups. Multivariable mixed-effects regression analyses adjusted for confounders showed similar oocyte count (incidence rate ratios [IRR] 0.96, 95% confidence interval [CI] 0.89-1.03), mature oocyte count (IRR 0.95, 95% CI 0.87-1.03), blastocyst count (IRR 1.12, 95% CI 0.97-1.29), and euploid blastocyst count (IRR 1.08, 95% CI 0.86-1.36). Euploidy rate per biopsy was similar between the progestin protocol and the GnRH antagonist protocol, and no significant interaction was detected between the protocol and patient age. Twenty-nine individuals, who underwent two stimulation cycles, one with progestin protocol and another with GnRH antagonist protocol, in any order, within the same calendar year, had similar metaphase II oocyte yields, blastocyst counts, and euploidy rates with both protocols.
CONCLUSION: The present study provides reassurance about the newer progestin protocol by demonstrating similar euploidy rates of blastocysts with GnRH antagonist protocols.
DESIGN: Retrospective cohort study.
SUBJECTS: Women undergoing assisted reproductive technology cycles with their own oocytes.
EXPOSURE: Ovarian stimulation was commenced on day 2/3 of the cycle, and either the GnRH-antagonist protocol was employed or the progestin protocol with dydrogesterone at a dose of 30 mg/d in three divided doses was started on the same day with gonadotropins or the day after and continued until (including) the day of final oocyte maturation.
MAIN OUTCOME MEASURES: Blastocyst euploidy rates.
RESULTS: A total of 4,755 stimulation cycles were included in the study, and 973 GnRH antagonist and 398 propensity score-matched progestin protocol cycles were included in the analyses. In bivariate comparisons, mature oocyte yield, number of zygotes, blastocysts, euploid blastocysts, and euploidy rate per biopsied blastocyst were similar between the groups. Multivariable mixed-effects regression analyses adjusted for confounders showed similar oocyte count (incidence rate ratios [IRR] 0.96, 95% confidence interval [CI] 0.89-1.03), mature oocyte count (IRR 0.95, 95% CI 0.87-1.03), blastocyst count (IRR 1.12, 95% CI 0.97-1.29), and euploid blastocyst count (IRR 1.08, 95% CI 0.86-1.36). Euploidy rate per biopsy was similar between the progestin protocol and the GnRH antagonist protocol, and no significant interaction was detected between the protocol and patient age. Twenty-nine individuals, who underwent two stimulation cycles, one with progestin protocol and another with GnRH antagonist protocol, in any order, within the same calendar year, had similar metaphase II oocyte yields, blastocyst counts, and euploidy rates with both protocols.
CONCLUSION: The present study provides reassurance about the newer progestin protocol by demonstrating similar euploidy rates of blastocysts with GnRH antagonist protocols.